Publications in collaboration with researchers from Memorial Sloan Kettering Cancer Center (14)

2022

  1. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC

    Blood, Vol. 140, Núm. 5, pp. 419-437

2021

  1. Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics

    EMBO Molecular Medicine, Vol. 13, Núm. 12

  2. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

  3. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

2019

  1. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAFV600E mutation

    Journal of Experimental Medicine, Vol. 216, Núm. 5, pp. 1061-1070

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

  2. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: A multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

    Annals of Oncology, Vol. 28, Núm. 10, pp. 2517-2525

  3. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

    Nature, Vol. 546, Núm. 7660, pp. 676-680

2016

  1. Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers

    Nature Communications, Vol. 7

2015

  1. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3766-3773

2014

  1. RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway

    Cancer Cell, Vol. 26, Núm. 1, pp. 61-76

2011

  1. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2598-2607

  2. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

    Blood